{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:51:34Z","timestamp":1791942694567,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40744-025-00788-0","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:55:37Z","timestamp":1758272137000},"page":"1043-1055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct00741793","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-8476","authenticated-orcid":false,"given":"Regan","family":"Arendse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-2731","authenticated-orcid":false,"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4740-6811","authenticated-orcid":false,"given":"Dalton","family":"Sholter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Rachich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marilise","family":"Marrache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-7919","authenticated-orcid":false,"given":"Allen J.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odalis","family":"Asin-Milan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"788_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100519","volume":"23","author":"IC Scott","year":"2022","unstructured":"Scott IC, Whittle R, Bailey J, et al. Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: an observational study using primary care electronic health record data. Lancet Reg Health Eur. 2022;23: 100519.","journal-title":"Lancet Reg Health Eur"},{"key":"788_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40744-019-00172-9","volume":"6","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Liu M, Rebello S, et al. Comparative disease burden in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis: data from two Corrona registries. Rheumatol Ther. 2019;6:529\u201342.","journal-title":"Rheumatol Ther"},{"key":"788_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123582","volume":"10","author":"B Michelsen","year":"2015","unstructured":"Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS ONE. 2015;10: e0123582.","journal-title":"PLoS ONE"},{"key":"788_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3399\/bjgp18X695705","volume":"68","author":"H Jethwa","year":"2018","unstructured":"Jethwa H, Abraham S. Biologic agents in inflammatory arthritis. Br J Gen Pract. 2018;68:204\u20135.","journal-title":"Br J Gen Pract"},{"key":"788_CR5","unstructured":"SIMPONI (golimumab). Highlights of prescribing information. 2018 [cited 2023 28SEP2023]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125289s139lbl.pdf."},{"key":"788_CR6","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","volume":"61","author":"AM Kerola","year":"2022","unstructured":"Kerola AM, Kazemi A, Rollefstad S, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford). 2022;61:4656\u201366.","journal-title":"Rheumatology (Oxford)"},{"key":"788_CR7","first-page":"430","volume":"32","author":"C Book","year":"2005","unstructured":"Book C, Saxne T, Jacobsson LT. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol. 2005;32:430\u20134.","journal-title":"J Rheumatol"},{"key":"788_CR8","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3899\/jrheum.160070","volume":"43","author":"K Juneblad","year":"2016","unstructured":"Juneblad K, Rantap\u00e4\u00e4-Dahlqvist S, Alenius GM. Disease activity and increased risk of cardiovascular death among patients with psoriatic arthritis. J Rheumatol. 2016;43:2155\u201361.","journal-title":"J Rheumatol"},{"key":"788_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res Hoboken. 2016;68:744\u201352.","journal-title":"Arthritis Care Res Hoboken"},{"key":"788_CR10","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5\u2005years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689\u201394.","journal-title":"Ann Rheum Dis"},{"key":"788_CR11","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr., Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum"},{"key":"788_CR12","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.160420","volume":"43","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;43:2120\u201330.","journal-title":"J Rheumatol"},{"key":"788_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s41927-020-00145-4","volume":"4","author":"P Rahman","year":"2020","unstructured":"Rahman P, Baer P, Keystone E, et al. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. BMC Rheumatol. 2020;4:46.","journal-title":"BMC Rheumatol"},{"key":"788_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036245","volume":"10","author":"P Rahman","year":"2020","unstructured":"Rahman P, Arendse R, Khraishi M, et al. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry. BMJ Open. 2020;10: e036245.","journal-title":"BMJ Open"},{"key":"788_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s41927-020-00158-z","volume":"4","author":"P Rahman","year":"2020","unstructured":"Rahman P, Starr M, Haaland D, et al. Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry. BMC Rheumatol. 2020;4:56.","journal-title":"BMC Rheumatol"},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/JCMA.0000000000000673","volume":"85","author":"CC Wang","year":"2022","unstructured":"Wang CC, Tseng KS, Tsao YP, et al. Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: a two-center study in Taiwan. J Chin Med Assoc. 2022;85:175\u201382.","journal-title":"J Chin Med Assoc"},{"key":"788_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021082","volume":"8","author":"K Kruger","year":"2018","unstructured":"Kruger K, Burmester GR, Wassenberg S, et al. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open. 2018;8: e021082.","journal-title":"BMJ Open"},{"key":"788_CR18","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40744-021-00352-6","volume":"8","author":"H Kim","year":"2021","unstructured":"Kim H, Kim Y, Lee Y. Real-world safety and effectiveness of golimumab in rheumatic diseases: post-marketing surveillance in Korea. Rheumatol Ther. 2021;8:1393\u2013404.","journal-title":"Rheumatol Ther"},{"key":"788_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, et al. Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2017;47:108\u201314.","journal-title":"Semin Arthritis Rheum"},{"key":"788_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.55563\/clinexprheumatol\/zizo0l","volume":"39","author":"RM Flipo","year":"2021","unstructured":"Flipo RM, Tubach F, Goupille P, et al. Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study. Clin Exp Rheumatol. 2021;39:537\u201345.","journal-title":"Clin Exp Rheumatol"},{"key":"788_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152461","volume":"67","author":"A Goldman","year":"2024","unstructured":"Goldman A, Galper BL, Druyan A, et al. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports. Semin Arthritis Rheum. 2024;67: 152461.","journal-title":"Semin Arthritis Rheum"},{"key":"788_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/acr.22290","volume":"66","author":"C Thorne","year":"2014","unstructured":"Thorne C, Bensen WG, Choquette D, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res Hoboken. 2014;66:1142\u201351.","journal-title":"Arthritis Care Res Hoboken"},{"key":"788_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41927-023-00329-8","volume":"7","author":"A Broadwell","year":"2023","unstructured":"Broadwell A, Schechtman J, Conaway D, et al. Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study. BMC Rheumatol. 2023;7:5.","journal-title":"BMC Rheumatol"},{"key":"788_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40744-021-00354-4","volume":"8","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Chakravarty SD, Black S, et al. Incidence of infusion reactions and clinical effectiveness of intravenous golimumab versus infliximab in patients with rheumatoid arthritis: the real-world AWARE study. Rheumatol Ther. 2021;8:1551\u201363.","journal-title":"Rheumatol Ther"},{"key":"788_CR25","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3899\/jrheum.190260","volume":"47","author":"LR Harrold","year":"2020","unstructured":"Harrold LR, Griffith J, Zueger P, et al. Long-term, real-world safety of adalimumab in rheumatoid arthritis: analysis of a prospective US-based registry. J Rheumatol. 2020;47:959\u201367.","journal-title":"J Rheumatol"},{"key":"788_CR26","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1002\/art.34582","volume":"64","author":"JF Simard","year":"2012","unstructured":"Simard JF, Neovius M, Askling J. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum. 2012;64:3502\u201310.","journal-title":"Arthritis Rheum"},{"key":"788_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","volume":"74","author":"LK Mercer","year":"2015","unstructured":"Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74:1087\u201393.","journal-title":"Ann Rheum Dis"},{"key":"788_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","volume":"77","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:905\u201310.","journal-title":"Ann Rheum Dis"},{"key":"788_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1496-5","volume":"20","author":"LR Harrold","year":"2018","unstructured":"Harrold LR, Litman HJ, Saunders KC, et al. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018;20: 2.","journal-title":"Arthritis Res Ther"},{"key":"788_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","volume":"155","author":"MP Lee","year":"2019","unstructured":"Lee MP, Desai RJ, Jin Y, et al. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 2019;155:700\u20137.","journal-title":"JAMA Dermatol"},{"key":"788_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"SC Kim","year":"2018","unstructured":"Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2018;48:399\u2013405.","journal-title":"Semin Arthritis Rheum"},{"key":"788_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","volume":"10","author":"CA Salinas","year":"2023","unstructured":"Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2023;10:201\u201323.","journal-title":"Rheumatol Ther"},{"key":"788_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.berh.2011.10.007","volume":"25","author":"KI Salomon-Escoto","year":"2011","unstructured":"Salomon-Escoto KI, Gravallese EM, Kay J. Assessment of control of rheumatoid arthritis disease activity. Best Pract Res Clin Rheumatol. 2011;25:497\u2013507.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"788_CR34","doi-asserted-by":"publisher","unstructured":"Coates LC, Rahman P, Psaradellis E, et al. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. Rheumatology (Oxford). 2019;58(3):522-6. https:\/\/doi.org\/10.1093\/rheumatology\/key359","DOI":"10.1093\/rheumatology\/key359"},{"key":"788_CR35","doi-asserted-by":"crossref","unstructured":"Gossec L. Chapter 5\u2014monitoring of disease and treatment of patients with rheumatic disease. In: Handbook of systemic autoimmune diseases, vol 15. 2018. p. 97\u2013125.","DOI":"10.1016\/B978-0-444-63887-8.00005-0"},{"key":"788_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.","journal-title":"Health Qual Life Outcomes"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00788-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:46:42Z","timestamp":1763732802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00788-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00788-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Regan Arendse has not declared any conflicts of interest relevant to this study; Proton Rahman has received consulting fees from Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Novartis, and Pfizer, and has also received research grants from Johnson & Johnson and Novartis; Philip Baer has received consulting fees from AbbVie, Amgen, AstraZeneca, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, GlaxoSmithKline, Innomar, JAMP Pharma, Johnson & Johnson, McKesson, Novartis, Opticann, Organon, Pfizer, Teva, and Viatris; Derek Haaland has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda, and UCB; Louis Bessette reports speaker\u2019s bureau for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Johnson & Johnson, MSD, Novartis, Organon, Pfizer, Sandoz, Sanofi, Teva, and UCB; consulting for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Gilead, Johnson & Johnson, MSD, Novartis, Organon, Pfizer, Sandoz, Sanofi, Teva, and UCB; grant\/research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Sanofi, and UCB. Dalton Sholter has not declared any conflicts of interest relevant to this study; Meagan Rachich and Odalis Asin-Milan are employees of Johnson & Johnson; Anne Marilise Marrache and Allen J Lehman are former employees of Johnson & Johnson; this work was done while they were employees; Anne Marilise Marrache is a current employee of Lundbeck Canada Inc; Allen J Lehman is a current employee of Novartis; Emmanouil Rampakakis is an employee of JSS Medical Research and is a paid consultant of Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The BioTRAC study was conducted in accordance with the Declaration of Helsinki. Ethics approval was obtained from a central Research Ethics Board (REB) IRB Service, Ontario, Canada now known as Advarra, for private practices and from respective REBs for institutional sites: Sunnybrook Health Sciences Centre REB, Winnipeg Clinical Ethics Committee, Mount Sinai Hospital REB, University of British Columbia REB, CHUS Centre de Recherche, Health Research Ethics Board of Alberta, Horizon Health Network REB, and H\u00f4pital Maisonneuve-Rosemont. Prior to enrolment, patients were required to provide written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}